Genetix Group Announces Directorate Change
News Nov 30, 2005
The Board of Genetix Group plc has announced that Trevor Bell, Chief Operating Officer, will be resigning from the Board with effect from 11th January 2006.
Trevor is leaving the company as a consequence of changes planned for the composition of the Board which will result in the role of Chief Operating Officer becoming redundant.
With its new generation of products in the field of cell biology, the Board has identified a need to further strengthen its scientifically driven expertise at Board level.
Commenting on Trevor’s departure, John Morgan, Chairman said, "The Board would like to thank Trevor for the very significant contribution that he has made to Genetix."
"His professionalism and the impact that his wide-ranging business experience has brought to the company has been highly appreciated and he has participated actively in the decision to restructure the Board along the above lines. We wish Trevor every success in the future."
New Inherited Neurodevelopmental Disease DiscoveredNews
Researchers have identified a new inherited neurodevelopmental disease that causes slow growth, seizures and learning difficulties in humans.READ MORE
BioAscent Establishes Integrated Drug Discovery Services OfferingNews
Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.READ MORE
Lab Innovations returns to the NEC, Bimingham , UKNews
Save the date for the UK’s only lab-dedicated exhibition showcase!READ MORE
Comments | 0 ADD COMMENT
International Conference on Biobetters and Regulatory Affairs
Jun 27 - Jun 28, 2018